Two types of anti-transferrin receptor nanobodies improve tracking of transplants via PET/CT, highlighting specificity and kinetics.
Two anti-transferrin receptor (TfR) nanobodies, V H H123 specific for mouse TfR and V H H188 specific for human TfR, were used to track transplants non-invasively by PET/CT in mouse models, without the need for genetic modification of the transferred cells. We provide a comparison of the specificity and kinetics of the PET signals acquired when using nanobodies radiolabeled with 89 Zr, 64 Cu, and 18 F, and find that the chelation of the 89 Zr and 64 Cu radioisotopes to anti-TfR nanobodies results in radioisotope release upon endocytosis of the radiolabeled nanobodies. We used a knock-in mouse that expresses a TfR with a human ectodomain (Tfrc hu/hu ) as a source of bone marrow for transplants into C57BL/6 recipients and show that V H H188 detects such transplants by PET/CT. Conversely, C57BL/6 bone marrow and B16.F10 melanoma cell line transplanted into Tfrc hu/hu recipients can be imaged with V H H123. In C57BL/6 mice impregnated by Tfrc hu/hu males, we saw an intense V H H188 signal in the placenta, showing that TfR-specific V H Hs accumulate at the placental barrier but do not enter the fetal tissue. We were unable to observe accumulation of the anti-TfR radiotracers in the central nervous system (CNS) by PET/CT but showed evidence of CNS accumulation by radiospectrometry. The model presented here can be used to track many transplanted cell types by PET/CT, provided cells express TfR, as is typically the case for proliferating cells such as tumor lines.
No takes yet. Share an insight, caveat, or question.
Balligand et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: